# Randomised trial of surgical resection with or without pre-operative chemotherapy in patients with operable non-small cell lung cancer (NSCLC) of any stage

Submission date 06/04/2000	Recruitment status  No longer recruiting	Prospectively registered Protocol		
Registration date	Overall study status	☐ Statistical analysis plan		
06/04/2000	Completed	[X] Results		
Last Edited	Condition category	[] Individual participant data		
22/10/2018	Cancer			

## Plain English summary of protocol

Not provided at time of registration

# Contact information

# Type(s)

Scientific

#### Contact name

**Prof Ian Smith** 

#### Contact details

Department of Oncology Royal Marsden Hospital Downs Road Sutton United Kingdom SM2 5PT +44 (0)20 8642 6011 abc@123.com

# Additional identifiers

**EudraCT/CTIS** number

IRAS number

ClinicalTrials.gov number

#### Secondary identifying numbers

LU22

# Study information

#### Scientific Title

Randomised trial of surgical resection with or without pre-operative chemotherapy in patients with operable non-small cell lung cancer (NSCLC) of any stage

#### **Study objectives**

To compare survival following surgical resection with or without pre-operative chemotherapy.

#### Secondary aims are to compare:

- 1. QL throughout the survival period; all items on the SF-36 questionnaire will be used to assess physical, emotional and functional health status, with particular emphasis on items that reflect the impact of symptoms on activities
- 2. Pre-randomisation clinical and post-surgery pathological staging
- 3. Resectability rates
- 4. Extent of surgery
- 5. Time to and site of relapse

And chemotherapy group, to document response evaluated according to the subjective investigators opinion following the WHO (1979) criteria, and clinician's assessment of the adverse effects of chemotherapy.

# Ethics approval required

Old ethics approval format

# Ethics approval(s)

Not provided at time of registration

# Study design

Randomised controlled trial

# Primary study design

Interventional

# Secondary study design

Randomised controlled trial

# Study setting(s)

Hospital

# Study type(s)

Treatment

## Participant information sheet

## Health condition(s) or problem(s) studied

Non-small cell lung cancer (NSCLC)

#### **Interventions**

- 1. One group receives surgical resection with pre-operative chemotherapy.
- 2. The other group receives surgical resection alone.

#### Intervention Type

Other

#### Phase

Not Specified

#### Primary outcome measure

Survival, quality of life, pre-randomisation clinical and post-surgery pathological staging, resectability rates, extent of surgery, time to and site of relapse

#### Secondary outcome measures

- 1. QL assessed before randomisation at 6 and 12 months from randomisation, and then annually, using the SF-36 questionnaire. All items and subscales will be examined according to the SF-36 manual. Analysis will be based on comparisons between regimens at the designated time points and on change from baseline for each regimen
- 2.Pre-randomisation clinical and post-surgery pathological staging
- 3. Resectability rates
- 4. Extent of surgery
- 5. Time to and site of relapse

## Overall study start date

01/07/1997

#### Completion date

29/07/2004

# Eligibility

#### Key inclusion criteria

- 1. Previously untreated non small cell lung cancer
- 2. Tumour considered resectable
- 3. Either sex, any age
- 4. No evidence of distant metastases
- 5. Considered fit for chemotherapy and proposed surgical resection
- 6. WHO performance status 0, 1 or 2
- 7. No contraindication to chemotherapy or surgery
- 8. No other disease or previous malignancy likely to interfere with the protocol treatments
- 9. Patient willing and able to complete SF-36 questionnaires

#### Participant type(s)

Patient

#### Age group

## **Not Specified**

#### Sex

Both

# Target number of participants

600

# Key exclusion criteria

Not provided at time of registration.

#### Date of first enrolment

01/07/1997

#### Date of final enrolment

29/07/2004

# Locations

# Countries of recruitment

England

**United Kingdom** 

# Study participating centre Department of Oncology

Sutton United Kingdom SM2 5PT

# Sponsor information

#### Organisation

Medical Research Council (MRC) (UK)

# Sponsor details

20 Park Crescent London United Kingdom W1B 1AL +44 (0)20 7636 5422 clinical.trial@headoffice.mrc.ac.uk

#### Sponsor type

Research council

#### Website

http://www.mrc.ac.uk

# Funder(s)

#### Funder type

Research council

#### Funder Name

Medical Research Council (MRC) (UK)

#### Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, MRC

# **Funding Body Type**

Government organisation

# **Funding Body Subtype**

National government

#### Location

**United Kingdom** 

# **Results and Publications**

# Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

#### IPD sharing plan summary

Not provided at time of registration

## **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Plain English results				No	Yes
Results article	results	09/06/2007		Yes	No